Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net income	$ 4,851	$ 4,187
Adjustments to reconcile net income to net cash provided by/(used in) operating activities:
Depreciation and amortization	329	316
Impairment of intangible assets	50	0
Noncash lease expense	96	108
Stock-based compensation	511	469
Deferred income tax expense (benefit)	(95)	41
Other investment (gains)	(128)	0
Net (gains) losses within CIPs	(325)	(116)
Net (purchases) proceeds within CIPs	(2,276)	(1,387)
(Earnings) losses from equity method investees	(119)	(304)
Distributions of earnings from equity method investees	41	32
Changes in operating assets and liabilities:
Accounts receivable	(410)	(607)
Investments, trading	(34)	52
Other assets	(561)	(1,410)
Accrued compensation and benefits	(297)	(479)
Accounts payable and accrued liabilities	225	(67)
Other liabilities	480	1,332
Net cash provided by/(used in) operating activities	2,338	2,167
Investing activities
Purchases of investments	(586)	(681)
Proceeds from sales and maturities of investments	646	270
Distributions of capital from equity method investees	344	26
Net consolidations (deconsolidations) of sponsored investment funds	(98)	21
Acquisition, net of cash acquired	(74)	(189)
Purchases of property and equipment	(165)	(220)
Net cash provided by/(used in) investing activities	67	(773)
Financing activities
Repayments of long-term borrowings	(1,000)	0
Proceeds from long-term borrowings	5,474	1,238
Cash dividends paid	(2,310)	(2,292)
Proceeds from stock options exercised	247	51
Repurchases of common stock	(1,544)	(1,500)
Net proceeds from (repayments of) borrowings by CIPs	(25)	(38)
Net subscriptions received/(redemptions/distributions paid) from noncontrolling interest holders	1,991	1,032
Other financing activities	(19)	20
Net cash provided by/(used in) financing activities	2,814	(1,489)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	82	(5)
Net increase/(decrease) in cash, cash equivalents and restricted cash	5,301	(100)
Cash, cash equivalents and restricted cash, beginning of period	8,753	7,433
Cash, cash equivalents and restricted cash, end of period	14,054	7,333
Supplemental schedule of noncash investing and financing transactions:
Issuance of common stock	439	554
Increase (decrease) in noncontrolling interests due to net consolidation (deconsolidation) of sponsored investment funds	$ (1,590)	$ (129)